Abstract:Abstract Background Endoscopic healing (EH) is the major long-term treatment target for inflammatory bowel diseases (IBD) in adults and paediatric patients. However, EH may not represent disease clearance. Hence, risk of relapse remains high and treatment discontinuation after reaching EH often results in disease exacerbation. We aimed to identify persistent cellular, molecular and microbial drivers of IBD under EH and longitudinally collected endoscopic biopsies from paediatric patients for analysis of single T-cell and bulk transcriptomics as well as mucosa-associated microbiota. Methods We followed disease trajectories of paediatric IBD patients treated according to international guidelines and collected mucosal biopsies from the terminal ileum (TI) and sigmoid colon (SC) at baseline (T1) and after approximately 3-12 months (T2) to assess EH. Non-IBD controls showed no macroscopic or histologic signs of inflammation. Host RNA and bacterial DNA were simultaneously extracted from single biopsies for bulk RNA-seq, and 16S rRNA seq. A second biopsy was used for isolation of lamina propria mononuclear cells (LPMCs), followed by CD45+, CD3+ cell sorting and single T-cell analysis (10X Genomics). Data were quality controlled and integrated. Results 217 biopsies (135 simultaneous extraction of host RNA and bacterial DNA; 82 single T-cell analysis) from 32 paediatric IBD patients (mean age 13 ± 3.5 years, 21 Crohn’s disease [CD], 11 ulcerative colitis [UC]; T1 = 32, T2 = 32, T > 2 = 6) and 5 non-IBD controls were analysed. Time between T1 and T2 averages 40 ± 22 weeks. At baseline, 15 patients (14 CD, 1 UC) were newly diagnosed and 31/32 patients had active mucosal inflammation. Twenty-two patients (71%) achieved EH at T2 (SES-CED ≤2 and absence of ulcerations), mostly on anti-TNF therapy. One patient (EH at T1) experienced relapsing disease within 10 weeks after discontinuing medication. In the bulk RNA-seq, we identified 299 differential expressed genes (DEGs; corrected p-value <0.05, FC >2.0), such as DUOX2, SAA2-SAA4, FCGR3B and NOS2, that are associated with active IBD and remained upregulated in EH in contrast to non-IBD controls. In addition single cell analysis revealed an IBD-specific pathogenic Th17 cluster that continued to exist in EH and showed high correlation with top DEGs after data integration. 16S rRNA gene seq highlighted highly individual mucosa-associated bacterial profiles and a reduced α-diversity in active and EH compared to non-IBD controls. Conclusion A persisting IBD signature in EH reflects ongoing cellular, molecular and microbial activity in comparison to non-IBD controls despite EH and mucosal regeneration. These markers may provide targets for future or sequential therapies.

DOP066. Impaired Mucosal Permeability Underlies Ongoing Irritable Bowel Syndrome-Like Symptoms, in Patients with Inflammatory Bowel Disease Who Have Achieved Mucosal Healing

Endoscopy Assessment at 1-Year Identifies Long-Term Responders to Thiopurines Maintenance Therapy in Patients With Crohn's Disease.

P355 Exceeding treatment expectations in Crohn’s disease: transmural healing and a new definition of deep remission

Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn'S Disease

Exploring the concept of deep remission in Crohn’s disease: correlation between transmural healing and biomarkers

Mucosal Healing Did Not Predict Sustained Clinical Remission In Patients With Ibd After Discontinuation Of One-Year Infliximab Therapy

Normalization of C-Reactive Protein Predicts Better Outcome in Patients with Crohn's Disease with Mucosal Healing and Deep Remission

P755 Long-term need for restart of biologics after withdrawal in patients with Inflammatory Bowel Disease in mucosal healing

P577 Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort Study

Mucosal Healing in Ileocolonic Crohn′s Diseases with Short-Term Infliximab and Immunosuppression Combined Therapy

Design How / When Concomitant IMMs [ n ( % ) ] Fecal Calprotectin ( μ g / g ) Blood In fl ammatory Markers Clinical Studies Predictors

Discontinuation of Biological Treatments in Inflammatory Bowel Disease

Thiopurines Prevented Surgical Recurrence in Patients with Crohn's Disease after Intestinal Resection: Strategy Based on Risk Stratification.

Mucosal Healing is Associated with the Reduced Disabling Disease in Crohn's Disease.

P402 Discontinuation of Short-Term Infliximab Maintenance Therapy in Patients with Crohn's Disease: Outcomes and Risk Factors Associated with Relapse

Characteristics of mucosa-associated gut microbiota during treatment in Crohn's disease.

Long-term outcomes and associated factors of Crohn's disease patients achieving transmural healing based on magnetic resonance enterography: a Chinese retrospective cohort study

P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study

Safety Profile of Thiopurines in Crohn Disease

De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice

OP04 Endoscopic healing in paediatric IBD perpetuates a persistent signature characterized by pathogenic Th17 cells and tissue-associated molecular and microbial drivers of disease